文献速递肝病消化道肿瘤与早癌

非增强磁共振成像与超声用于肝细胞癌监测的比较:一项随机单中心试验

Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance: A Randomized, Single-Center Trial.
PubMed 文献 · Gastroenterology · 2025-01-22

在韩国单中心随机非盲试验中,414例Child-Pugh A级肝硬化患者1:1分配接受超声或非增强MRI联合血清甲胎蛋白监测。两组BCLC 0/A期肿瘤检出率无显著差异(7% vs 12%),但MRI组BCLC 0期检出更多(8% vs 2%)、分期更早(P=0.014)且假阳性转诊率更低(0.7% vs 3.1%,P<0.001)。

要点

  • 非增强MRI与超声监测BCLC 0/A期肿瘤检出率无显著差异(7% vs 12%)
  • MRI组BCLC 0期检出率8%,高于超声组的2%
  • MRI组假阳性转诊率0.7%,低于超声组的3.1%(P<0.001)

核心结论

  • 非增强MRI是肝硬化患者监测的更好替代方案,可提供更早的初始诊断分期和更低的假阳性转诊率。

研究设计与样本

  • 韩国单中心随机非盲试验,2015年6月至2017年11月筛查416例,纳入414例20至70岁Child-Pugh A级肝硬化且无肝癌或其他近期恶性肿瘤史患者,1:1分配至超声组(n=207)或非增强MRI组(n=207)。
  • 参与者接受最多10次每半年一次的超声或非增强MRI联合血清甲胎蛋白监测。
  • 主要终点为BCLC 0或A期肿瘤检出率、初始诊断时分期分布及假阳性转诊率。

主要发现

  • 截至2022年11月,超声组23例、MRI组25例被诊断为肝癌。
  • BCLC 0或A期肿瘤检出率超声组7%(95%CI 4%-11%) vs MRI组12%(95%CI 8%-17%),两组无显著差异。
  • BCLC 0期肿瘤MRI组检出率8% vs 超声组2%。
  • MRI组BCLC分期更早(P=0.014)。
  • 假阳性转诊率MRI组0.7%(95%CI 0.4%-1.2%) vs 超声组3.1%(95%CI 2.3%-4.1%),P<0.001。

临床怎么用

  • 作者认为非增强MRI是肝硬化患者监测中优于超声的替代方案,可提供更早的初始诊断分期和更低的假阳性转诊率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This study aimed to compare ultrasonography (US) and noncontrast magnetic resonance imaging (MRI) in the surveillance of hepatic malignancy. METHODS: We conducted a randomized, nonblinded trial at a single center in South Korea. Eligible individuals were aged 20 to 70 years with liver cirrhosis, Child-Pugh class A, and no history of liver cancer or other recent malignancy. Participants were randomized 1:1 to receive up to 10 semiannual surveillance using US or noncontrast MRI with serum alpha-fetoprotein testing. The primary endpoints were the detection rates of Barcelona Clinic Liver Cancer (BCLC) stage 0 or A tumors, stage distribution at initial diagnosis, and false-positive referral rates. RESULTS: From June 2015 to November 2017, 416 patients were screened, and 414 were enrolled and assigned to the US (n = 207) or MRI (n = 207) group. In total, 23 participants in the US group and 25 in the MRI group were diagnosed with liver cancer by November 2022. The detection rates of BCLC stage 0 or A tumors were not different between the US and MRI groups (7% [95% confidence interval (CI), 4%-11%] vs 12% [8%-17%]). BCLC stage 0 tumors were more frequently detected in the MRI group than in the US group (8% vs 2%). The MRI group had earlier BCLC stage (P = .014) and lower false-positive referral rate (0.7% [95% CI, 0.4%-1.2%] vs 3.1% [2.3%-4.1%], P < .001) compared with the US group. CONCLUSIONS: Noncontrast MRI is a better alternative to US for the surveillance of cirrhotic patients offering earlier stage at initial diagnosis and lower false-positive referral rate. (ClincalTrials.gov, Number: NCT02514434.).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Rhee H, Kim MJ, Kim DY, et al. Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance: A Randomized, Single-Center Trial. Gastroenterology. 2025. PMID: 39855314. doi:10.1053/j.gastro.2024.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。